HIBICLENS® HAND SOAP DISPENSER BY GP PRO (GEORGIA-PACIFIC), WHITE, 55058, 1 DISPENSER PER CASE

Description:

The Hibiclens® Antiseptic Skin Cleanser System by GP PRO combines the industry’s leading CHG (Chlorhexidine Gluconate) solution[1] with touchless dispensing technology. Hibiclens® is already trusted across the healthcare community and is the #1 pharmacist recommended antimicrobial soap.[2] And now, wall-mounted, automated dispensing provides an additional level of hygiene and convenience over common pump bottles.<p>Gentle, FDA-approved Hibiclens® has persistent antimicrobial effect with rapid bactericidal activity against a wide range of microorganisms.[4] It provides proven protection against germs that cause HAIs[6] and prevents skin infections, thereby reducing risk of cross-infection.[7] Also important for professionals who wash hands frequently: This 4% CHG solution is less irritating than other tested CHG formulations, and is compatible with Nitrile and Latex gloves.[8] FDA approved for use as a surgical hand scrub and healthcare personnel handwash.<p>Hibiclens® dispenser refills (45810) pair with automated dispensers that come in both black (55057) and white (55058) to match your existing décor.<p>SOURCES: [1]Hibiclens sales represent roughly half of the chlorhexidine gluconate (CHG) solution market, including all 2% and 4% solutions. [2]2019-2020 survey results, Pharmacy Times and U.S. News & World Report. [3]Does not replace the need of washing hands regularly. [4]Molnlycke Irritation Studies conducted by PRACS Institute Ltd. PRACS report# ROS-0225 and R05-0871. [5]Molylncke study by Peterson: HIB 3-107_10-2-1, Paulson, Daryl S. Comparative Evaluation of Five Surgical Hand Scrub Preparations. AORN Journal 1994; Col 60, NO 2:246-256. [6]Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992; 327:88--93. Wang E.W. and Layon A.J. Chlorhexidine gluconate use to prevent hospital acquired infections—a useful tool, not a panacea. Ann Transl Med. 2017 Jan; 5(1): 14. [7]Studies submitted to FDA, conducted by A. Peterson, HIB 3-107-10-1, HIB 3-107-10-2-1, HIB 4-107-1-5, HIB 4-107-1-6, HIB 4-107-1-7, HIB 4-107-1-8, HIB 4-107-1-8-1. [8]GP PRO Proprietary Research: WP200531.